AT
Andrew Tsai
Executive
Andrew Tsai is an analyst at Jefferies.
Notable Quotes
"decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."View Story →
"the decision on Tudriqev makes 'one less competitor' in the near-term for Iovance’s Amtagvi."View Story →
"the order is an 'official stamp of validation to the class,' showing that government support is real."View Story →
Related Stories
Psychedelic drug developers rally as Trump orders FDA to expedite reviews - Reuters
Psychedelic drug developers rally as Trump orders FDA to expedite reviews Reuters
April 20, 2026Replimune's drug for advanced skin cancer fails to win FDA nod again - Reuters
Replimune's drug for advanced skin cancer fails to win FDA nod again Reuters
April 10, 2026